Recursion Pharmaceuticals Q1 Earnings Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 48 minutes ago
0mins
Should l Buy RXRX?
Source: seekingalpha
- Earnings Performance: Recursion Pharmaceuticals reported a Q1 GAAP EPS of -$0.22, beating expectations by $0.04, yet revenue of $6.47 million fell short by $9.31 million, reflecting significant challenges in revenue growth.
- Cash Flow Status: As of March 31, 2026, the company had $665.2 million in cash and equivalents, down from $753.9 million as of December 31, 2025, indicating pressure on financial management that could impact future operational capabilities.
- Operating Expense Control: The cash operating expense for Q1 was $85.1 million, significantly lower than $120.2 million in the same period of 2025, demonstrating some success in cost control despite overall insufficient revenue.
- Funding Outlook: The company reiterated its guidance of less than $390 million in operational cash burn for 2026, expecting its cash runway to extend into early 2028, indicating a relatively stable financial plan without additional financing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RXRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RXRX
Wall Street analysts forecast RXRX stock price to rise
6 Analyst Rating
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 3.520
Low
5.00
Averages
7.75
High
11.00
Current: 3.520
Low
5.00
Averages
7.75
High
11.00
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Recursion Pharmaceuticals to Announce Q1 Earnings on May 6
- Earnings Announcement: Recursion Pharmaceuticals (RXRX) is set to announce its Q1 2023 earnings on May 6 before the market opens, with consensus EPS estimated at -$0.26 and revenue projected at $15.78 million, reflecting a 7% year-over-year increase.
- Earnings Estimate Changes: Over the past three months, EPS estimates have undergone five upward revisions and one downward revision, while revenue estimates have seen one upward and two downward revisions, indicating mixed market sentiment regarding the company's financial outlook.
- Competitive Pressure: Although Recursion is no longer viewed as merely an AI 'pet science project,' it continues to face competitive pressures from peers, leading analysts to adopt a cautious stance and label the stock as a 'sell' due to concerns about its market position.
- Executive Appointment: The recent appointment of Vicki Goodman as Chief Medical Officer (CMO) may be aimed at strengthening the company's medical strategy and market positioning in response to increasing industry competition.
See More
Recursion Pharmaceuticals Q1 Earnings Analysis
- Earnings Performance: Recursion Pharmaceuticals reported a Q1 GAAP EPS of -$0.22, beating expectations by $0.04, yet revenue of $6.47 million fell short by $9.31 million, reflecting significant challenges in revenue growth.
- Cash Flow Status: As of March 31, 2026, the company had $665.2 million in cash and equivalents, down from $753.9 million as of December 31, 2025, indicating pressure on financial management that could impact future operational capabilities.
- Operating Expense Control: The cash operating expense for Q1 was $85.1 million, significantly lower than $120.2 million in the same period of 2025, demonstrating some success in cost control despite overall insufficient revenue.
- Funding Outlook: The company reiterated its guidance of less than $390 million in operational cash burn for 2026, expecting its cash runway to extend into early 2028, indicating a relatively stable financial plan without additional financing.
See More
Recursion Achieves Significant Milestones in Drug Development
- Clinical Data Highlights: Early clinical data for REC-1245 in solid tumors demonstrate a well-tolerated safety profile with no dose-limiting toxicities (DLTs) observed, supporting ongoing dose escalation and showcasing its potential in cancer treatment.
- Strong Efficacy Signals: REC-4881 shows a 43% reduction in polyp burden in Phase 2 trials, with FDA engagement initiated to define a potential registrational pathway, updates expected in 2H26, which could open new market opportunities for the company.
- New Drug Development Progress: The first patient has been dosed in the ENLYGHT Phase 1 clinical study for REC-4539, designed to reduce platelet toxicity seen with other LSD1 inhibitors, indicating differentiated potential across solid tumors and hematologic malignancies.
- Robust Financial Performance: Recursion reiterates its guidance of less than $390 million operational cash burn for 2026, with cash runway expected to extend into early 2028, reflecting the company's disciplined capital execution and sustainability.
See More
Recursion Board Member Transition Announcement
- Board Member Transition: Recursion announced that founder Dr. Chris Gibson will complete his term in June 2026 and will not seek re-election, although he will continue as an advisor, a decision aimed at ensuring governance continuity and stability.
- Leadership Support: CEO Dr. Najat Khan expressed gratitude for Chris's contributions, emphasizing the importance of his support during the transition period, indicating the company's focus on valuing experience and guidance during leadership changes.
- Strategic Advisor Role: Dr. Chris Gibson stated he will continue to engage with Recursion as a strategic advisor, showcasing his confidence in the company's future while reflecting the company's appreciation for founder experience, aimed at driving long-term value creation.
- Platform Advantage: Recursion leverages its AI-driven drug discovery platform to develop innovative medicines in oncology, rare diseases, and other areas, highlighting its leading position in integrating biology and chemistry, aiming to accelerate drug development processes to meet patient needs.
See More
Recursion Pharmaceuticals Expands Partnership with Citeline to Enhance AI Drug Discovery
- Partnership Expansion: Recursion Pharmaceuticals has expanded its partnership with Citeline to integrate real-world data capabilities into its AI-driven drug discovery platform, thereby enhancing the efficiency of clinical trial design and development decisions.
- Drug Development Potential: Although Recursion has no market products yet, it boasts a substantial pipeline of potential drug products, including partnered programs with major pharmaceutical companies like Roche, Merck, Bayer, and Sanofi, indicating broad applicability in cancer and rare disease treatments.
- Strong Financial Position: By the end of 2025, Recursion had received over $500 million in milestone payments from partnered programs, with future potential payments exceeding $300 million, providing robust financial support for ongoing operations.
- Market Strategy: Recursion is considering an Amazon Prime-like subscription sales model for its drugs upon market entry, which could ensure revenue stability and attract more pharmaceutical companies to participate in promoting its drug offerings.
See More
Investment Opportunities and Risks in Artificial Intelligence
- AI Technology Transformation: Artificial intelligence is viewed as a transformative technology that could trigger paradigm shifts across various industries; while some companies have capitalized on investments, the overall sector is still in its early stages, presenting ongoing investment opportunities.
- Alphabet's AI Strategy: Alphabet has integrated AI modes and overviews into its search engine, boosting search traffic and user engagement, and although its stock has fallen 13% due to market volatility, its AI investments help solidify its market position.
- Recursion's Challenges: Recursion Pharmaceuticals focuses on leveraging AI to accelerate drug development, claiming to shorten clinical trial times, yet it has not launched any products and remains unprofitable, posing significant risks.
- Investment Risk Assessment: While Recursion could achieve breakthroughs in the future, the lack of market products and profitability suggests that investors with average risk tolerance should approach this stock with caution.
See More
Recursion Pharmaceuticals to Announce Q1 Earnings on May 6
- Earnings Announcement: Recursion Pharmaceuticals (RXRX) is set to announce its Q1 2023 earnings on May 6 before the market opens, with consensus EPS estimated at -$0.26 and revenue projected at $15.78 million, reflecting a 7% year-over-year increase.
- Earnings Estimate Changes: Over the past three months, EPS estimates have undergone five upward revisions and one downward revision, while revenue estimates have seen one upward and two downward revisions, indicating mixed market sentiment regarding the company's financial outlook.
- Competitive Pressure: Although Recursion is no longer viewed as merely an AI 'pet science project,' it continues to face competitive pressures from peers, leading analysts to adopt a cautious stance and label the stock as a 'sell' due to concerns about its market position.
- Executive Appointment: The recent appointment of Vicki Goodman as Chief Medical Officer (CMO) may be aimed at strengthening the company's medical strategy and market positioning in response to increasing industry competition.
See More
Recursion Pharmaceuticals Q1 Earnings Analysis
- Earnings Performance: Recursion Pharmaceuticals reported a Q1 GAAP EPS of -$0.22, beating expectations by $0.04, yet revenue of $6.47 million fell short by $9.31 million, reflecting significant challenges in revenue growth.
- Cash Flow Status: As of March 31, 2026, the company had $665.2 million in cash and equivalents, down from $753.9 million as of December 31, 2025, indicating pressure on financial management that could impact future operational capabilities.
- Operating Expense Control: The cash operating expense for Q1 was $85.1 million, significantly lower than $120.2 million in the same period of 2025, demonstrating some success in cost control despite overall insufficient revenue.
- Funding Outlook: The company reiterated its guidance of less than $390 million in operational cash burn for 2026, expecting its cash runway to extend into early 2028, indicating a relatively stable financial plan without additional financing.
See More
Recursion Achieves Significant Milestones in Drug Development
- Clinical Data Highlights: Early clinical data for REC-1245 in solid tumors demonstrate a well-tolerated safety profile with no dose-limiting toxicities (DLTs) observed, supporting ongoing dose escalation and showcasing its potential in cancer treatment.
- Strong Efficacy Signals: REC-4881 shows a 43% reduction in polyp burden in Phase 2 trials, with FDA engagement initiated to define a potential registrational pathway, updates expected in 2H26, which could open new market opportunities for the company.
- New Drug Development Progress: The first patient has been dosed in the ENLYGHT Phase 1 clinical study for REC-4539, designed to reduce platelet toxicity seen with other LSD1 inhibitors, indicating differentiated potential across solid tumors and hematologic malignancies.
- Robust Financial Performance: Recursion reiterates its guidance of less than $390 million operational cash burn for 2026, with cash runway expected to extend into early 2028, reflecting the company's disciplined capital execution and sustainability.
See More
Recursion Board Member Transition Announcement
- Board Member Transition: Recursion announced that founder Dr. Chris Gibson will complete his term in June 2026 and will not seek re-election, although he will continue as an advisor, a decision aimed at ensuring governance continuity and stability.
- Leadership Support: CEO Dr. Najat Khan expressed gratitude for Chris's contributions, emphasizing the importance of his support during the transition period, indicating the company's focus on valuing experience and guidance during leadership changes.
- Strategic Advisor Role: Dr. Chris Gibson stated he will continue to engage with Recursion as a strategic advisor, showcasing his confidence in the company's future while reflecting the company's appreciation for founder experience, aimed at driving long-term value creation.
- Platform Advantage: Recursion leverages its AI-driven drug discovery platform to develop innovative medicines in oncology, rare diseases, and other areas, highlighting its leading position in integrating biology and chemistry, aiming to accelerate drug development processes to meet patient needs.
See More
Recursion Pharmaceuticals Expands Partnership with Citeline to Enhance AI Drug Discovery
- Partnership Expansion: Recursion Pharmaceuticals has expanded its partnership with Citeline to integrate real-world data capabilities into its AI-driven drug discovery platform, thereby enhancing the efficiency of clinical trial design and development decisions.
- Drug Development Potential: Although Recursion has no market products yet, it boasts a substantial pipeline of potential drug products, including partnered programs with major pharmaceutical companies like Roche, Merck, Bayer, and Sanofi, indicating broad applicability in cancer and rare disease treatments.
- Strong Financial Position: By the end of 2025, Recursion had received over $500 million in milestone payments from partnered programs, with future potential payments exceeding $300 million, providing robust financial support for ongoing operations.
- Market Strategy: Recursion is considering an Amazon Prime-like subscription sales model for its drugs upon market entry, which could ensure revenue stability and attract more pharmaceutical companies to participate in promoting its drug offerings.
See More
Investment Opportunities and Risks in Artificial Intelligence
- AI Technology Transformation: Artificial intelligence is viewed as a transformative technology that could trigger paradigm shifts across various industries; while some companies have capitalized on investments, the overall sector is still in its early stages, presenting ongoing investment opportunities.
- Alphabet's AI Strategy: Alphabet has integrated AI modes and overviews into its search engine, boosting search traffic and user engagement, and although its stock has fallen 13% due to market volatility, its AI investments help solidify its market position.
- Recursion's Challenges: Recursion Pharmaceuticals focuses on leveraging AI to accelerate drug development, claiming to shorten clinical trial times, yet it has not launched any products and remains unprofitable, posing significant risks.
- Investment Risk Assessment: While Recursion could achieve breakthroughs in the future, the lack of market products and profitability suggests that investors with average risk tolerance should approach this stock with caution.
See More
